Wells Fargo & Company lowered shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) from an outperform rating to a market perform rating in a research report sent to investors on Sunday morning, Marketbeat.com reports.

IART has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an overweight rating and set a $65.00 price target on shares of Integra LifeSciences Holdings Corporation in a research note on Monday, July 10th. Zacks Investment Research raised Integra LifeSciences Holdings Corporation from a hold rating to a buy rating and set a $57.00 price target for the company in a research note on Tuesday, October 3rd. Raymond James Financial, Inc. lifted their price target on Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the stock an outperform rating in a research note on Thursday, July 27th. Oppenheimer Holdings, Inc. reaffirmed a buy rating on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, July 26th. Finally, TheStreet downgraded Integra LifeSciences Holdings Corporation from a b rating to a c+ rating in a research note on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Integra LifeSciences Holdings Corporation has a consensus rating of Buy and an average price target of $53.64.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). The firm had revenue of $278.83 million for the quarter, compared to analyst estimates of $286.00 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.35% and a net margin of 4.52%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the firm earned $0.93 EPS.

WARNING: This report was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://theolympiareport.com/2017/11/02/wells-fargo-company-downgrades-integra-lifesciences-holdings-corporation-iart-to-market-perform.html.

In related news, Director Barbara B. Hill acquired 10,768 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The stock was purchased at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the transaction, the director now owns 55,540 shares in the company, valued at approximately $2,591,496.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were bought at an average price of $49.25 per share, with a total value of $492,500.00. Following the transaction, the director now owns 29,612 shares in the company, valued at approximately $1,458,391. The disclosure for this purchase can be found here. Company insiders own 21.50% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC grew its holdings in Integra LifeSciences Holdings Corporation by 6.2% in the 2nd quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock valued at $440,690,000 after buying an additional 468,678 shares during the period. BlackRock Inc. grew its holdings in Integra LifeSciences Holdings Corporation by 307,726.8% in the 1st quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock valued at $314,104,000 after buying an additional 7,453,142 shares during the period. Vanguard Group Inc. grew its holdings in Integra LifeSciences Holdings Corporation by 116.7% in the 1st quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock valued at $238,289,000 after buying an additional 3,046,488 shares during the period. Capital Research Global Investors grew its holdings in Integra LifeSciences Holdings Corporation by 227.0% in the 2nd quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after buying an additional 2,705,488 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in Integra LifeSciences Holdings Corporation in the 2nd quarter valued at about $112,068,000. Institutional investors own 84.88% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.